Developer docs
API playgroundTry for free, no card

Search company profiles

Avisi Technologies

Full company profile

uuid0000f58

Namestring
Avisi Technologies
Legal namestring
Avisi Technologies, Inc.
Websiteurl
avisitech.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Avisi Technologies is a clinical-stage ophthalmic medical device company developing nanotechnology-enabled implants to treat open-angle glaucoma and related vision-loss conditions. Its core technology is a proprietary metamaterial platform combining alumina and Parylene-C, originally invented at the University of Pennsylvania's Singh Center for Nanotechnology, manufactured using MEMS (Micro-Electro-Mechanical Systems) micro-fabrication techniques to produce devices roughly 5 microns thick. The lead product, VisiPlate, is an ultrathin multichannel aqueous shunt designed to drain aqueous fluid from the anterior chamber to the subconjunctival space while avoiding the fibrotic scarring that causes failure of incumbent surgeries. The portfolio also includes VisiPlate-S, a suprachoroidal drainage device for mild-to-moderate glaucoma implanted during cataract surgery, and V-001, an early-stage sustained intraocular drug-delivery platform funded by NSF SBIR Phase II and IIB grants.

The company operates a vertical go-to-market targeting ophthalmologists, glaucoma specialists, and hospital/ASC-based surgical departments. Marketing is conducted through medical conferences (AAO, ASCRS, ESCRS, AGS, ARVO), peer-reviewed publications, key opinion leader relationships, and an active LinkedIn presence. Distribution is currently limited to investigational device shipments to 16 SAPPHIRE pivotal trial sites across 8 US states, with planned direct field sales to hospitals and ambulatory surgery centers post-FDA approval.

The business is pre-revenue. VisiPlate received FDA Investigational Device Exemption approval in October 2025, the first US patient was implanted in December 2025, and the company closed a $10.7M Series A in February 2026 (total funding ~$21.7M) to fund the SAPPHIRE pivotal trial and pipeline development. Reported 12-month VITA Trial outcomes — 42.6% mean diurnal IOP reduction and 46.7% medication-free patients with no serious adverse events — are the primary commercial validation to date. The 165-patient SAPPHIRE pivotal trial has an estimated completion date of October 2027.

Short descriptiontext

Avisi Technologies is a clinical-stage medical device company developing ultrathin nanotechnology-based glaucoma implants, including the VisiPlate aqueous shunt, targeting ophthalmologists and glaucoma specialists at hospitals and ambulatory surgery centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
glaucoma treatment devices, ophthalmic medical devices, intraocular pressure management, aqueous shunts, nanotechnology ophthalmology
Industry1 code
PRIMARYHLAHAJAI
Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Ophthalmic Goods3851
Product category
Ophthalmic Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales (Pre-commercial)
TypeHardware Sales
Description

Avisi Technologies is currently a clinical-stage company with no commercial revenue. The company is conducting FDA clinical trials for VisiPlate. Once approved, the company expects to generate revenue through direct sales of its VisiPlate aqueous shunt devices to hospitals, ambulatory surgery centers, and ophthalmology practices treating glaucoma patients.

avisitech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Avisi Technologies develops nanotechnology-enabled ophthalmic medical devices for the treatment of glaucoma and related eye conditions. Its core offering is VisiPlate, an investigational ultrathin (~5 micron) multichannel aqueous shunt made of patented alumina and Parylene-C metamaterial that controls intraocular pressure via redundant microchannels, with additional pipeline products including VisiPlate-S (suprachoroidal drainage device) and V-001 (sustained intraocular drug-delivery platform). The devices are manufactured using MEMS micro-fabrication techniques invented at the University of Pennsylvania.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 42.6% reduction in mean diurnal IOP at 12 months (from 24.1 to 13.1 mmHg)
+3 more records
Product overview1 text field

Avisi Technologies is a clinical-stage ophthalmic medical device company developing a portfolio of glaucoma treatment products leveraging proprietary nanotechnology and metamaterial technology. The core product is VisiPlate, an ultrathin multichannel aqueous shunt for moderate-severe glaucoma. This is complemented by VisiPlate-S, a suprachoroidal device designed for mild-moderate glaucoma during cataract surgery, and V-001, a sustained intraocular drug-delivery platform for dropless therapeutic delivery. The company uses MEMS (Micro-Electro-Mechanical Systems) manufacturing and advanced micro-fabrication techniques developed at the University of Pennsylvania.

Product and service3 records
1VisiPlate
CategoryOphthalmic surgical implant (glaucoma drainage device)
Description

VisiPlate is an investigational ultrathin multichannel aqueous shunt device designed to lower intraocular pressure in patients with open-angle glaucoma. The device is made of a patented metamaterial composition of alumina and Parylene-C, approximately 5 microns thick (several times thinner than a human hair), with multiple redundant microchannels that control aqueous drainage from the anterior chamber to the subconjunctival space. The non-fibrotic material design minimizes the scarring and blockage that causes failure of existing glaucoma surgical treatments.

2VisiPlate-S
CategoryOphthalmic surgical implant (suprachoroidal drainage device)
Description

VisiPlate-S is an investigational suprachoroidal drainage device designed for placement in the suprachoroidal space during cataract surgery to treat patients with mild-to-moderate primary open-angle glaucoma. The device is ultrathin, minimally invasive, soft and flexible, featuring a non-scarring design with a network of microchannels that create aqueous outflow through the suprachoroidal space via the uveoscleral pathway.

3V-001
CategoryOphthalmic drug-delivery platform
Description

V-001 is a thin-film sustained intraocular drug-delivery platform designed to provide controlled, sustained release of therapeutics (including dexamethasone) in the anterior chamber. The platform aims to create a dropless patient experience by reducing the compliance burden associated with topical eye drops for glaucoma and other eye disease treatment.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Avisi is a member of JLABS, Johnson & Johnson's premier life science incubator. The company was part of the inaugural JPOD resident cohort receiving support from concept to commercialization.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Selected for the Rosenman Innovators program supporting medtech startups with mentorship and resources for commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

VisiPlate technology was invented at the University of Pennsylvania through the Singh Center for Nanotechnology. Avisi was founded through the Y-Prize program and received support from Penn Engineering labs. Scientific advisors hail from Penn's Scheie Eye Institute.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Alumni of the MedTech Innovator Accelerator program, which provides mentorship and support for medical technology companies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Glaukos is the pioneer and market leader in MIGS devices (iStent family) for open-angle glaucoma. It is the most directly comparable peer to Avisi's VisiPlate, addressing the same patient population with similarly minimally invasive surgical implants targeting IOP reduction.

TypeDirect peer
Description

Sight Sciences markets the OMNI and Sustain systems, MIGS devices for glaucoma that combine trabecular and suprachoroidal outflow pathways. It directly competes with Avisi's VisiPlate and VisiPlate-S in the same ophthalmic surgical channels.

TypeBroad incumbent
Description

Alcon is a global ophthalmic medtech incumbent with a broad surgical and vision-care portfolio. It acquired Ivantis (Hydrus Microstent, a suprachoroidal MIGS device directly comparable to VisiPlate-S) and competes broadly across glaucoma surgical devices.

TypeBroad incumbent
Description

AbbVie, through its Allergan acquisition, markets the Xen Gel Stent (subconjunctival drainage device) and a broad ophthalmic pharmaceutical portfolio. Xen is the closest large-pharma competitor to VisiPlate in mechanism and indication.

TypeBroad incumbent
Description

Johnson & Johnson Vision is a leading ophthalmic medtech incumbent and the operator of JLABS, where Avisi is a resident company. J&J Vision sells cataract surgical products and has strategic interest in MIGS/glaucoma surgical adjacencies, making it both a competitor and potential acquirer.

TypeDirect peer
Description

New World Medical manufactures traditional glaucoma drainage devices (Ahmed, Baerveldt implants) that compete with VisiPlate in moderate-to-severe open-angle glaucoma. It is a relevant peer for surgical shunts in the same procedural category.

TypeBroad incumbent
Description

Bausch + Lomb is a major ophthalmic medtech incumbent with surgical and pharmaceutical glaucoma offerings. Its broad portfolio and global distribution make it a strategic competitor and potential acquirer of emerging glaucoma device companies like Avisi.

TypeEmerging player
Description

Iantrek is an early-to-growth-stage ophthalmic device company developing micro-invasive glaucoma surgical technologies, including canaloplasty and suprachoroidal approaches. It overlaps with Avisi in MIGS innovation targeting the same glaucoma surgeon customer base.

TypeEmerging player
Description

MicroOptx is a clinical-stage ophthalmic medtech company developing a suprachoroidal glaucoma drainage implant. It is a direct emerging-stage peer to Avisi's VisiPlate-S in the same suprachoroidal mechanism of action.

10Santen Pharmaceutical
TypeBroad incumbent
Description

Santen is a Japan-based global ophthalmology specialty pharmaceutical and device company with a substantial glaucoma franchise (including the InnFocus MicroShunt acquired from InnFocus). It is a strategic peer for both device and pharmaceutical glaucoma offerings overlapping Avisi's pipeline.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors24 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avisi Technologies

Ophthalmic Medical Devicesavisitech.com

Avisi Technologies is a clinical-stage medical device company developing ultrathin nanotechnology-based glaucoma implants, including the VisiPlate aqueous shunt, targeting ophthalmologists and glaucoma specialists at hospitals and ambulatory surgery centers.

What Avisi Technologies does

Avisi Technologies is a clinical-stage ophthalmic medical device company developing nanotechnology-enabled implants to treat open-angle glaucoma and related vision-loss conditions. Its core technology is a proprietary metamaterial platform combining alumina and Parylene-C, originally invented at the University of Pennsylvania's Singh Center for Nanotechnology, manufactured using MEMS (Micro-Electro-Mechanical Systems) micro-fabrication techniques to produce devices roughly 5 microns thick. The lead product, VisiPlate, is an ultrathin multichannel aqueous shunt designed to drain aqueous fluid from the anterior chamber to the subconjunctival space while avoiding the fibrotic scarring that causes failure of incumbent surgeries. The portfolio also includes VisiPlate-S, a suprachoroidal drainage device for mild-to-moderate glaucoma implanted during cataract surgery, and V-001, an early-stage sustained intraocular drug-delivery platform funded by NSF SBIR Phase II and IIB grants.

The company operates a vertical go-to-market targeting ophthalmologists, glaucoma specialists, and hospital/ASC-based surgical departments. Marketing is conducted through medical conferences (AAO, ASCRS, ESCRS, AGS, ARVO), peer-reviewed publications, key opinion leader relationships, and an active LinkedIn presence. Distribution is currently limited to investigational device shipments to 16 SAPPHIRE pivotal trial sites across 8 US states, with planned direct field sales to hospitals and ambulatory surgery centers post-FDA approval.

The business is pre-revenue. VisiPlate received FDA Investigational Device Exemption approval in October 2025, the first US patient was implanted in December 2025, and the company closed a $10.7M Series A in February 2026 (total funding ~$21.7M) to fund the SAPPHIRE pivotal trial and pipeline development. Reported 12-month VITA Trial outcomes — 42.6% mean diurnal IOP reduction and 46.7% medication-free patients with no serious adverse events — are the primary commercial validation to date. The 165-patient SAPPHIRE pivotal trial has an estimated completion date of October 2027.

Avisi Technologies firmographics

Firmographics
Name
Avisi Technologies
Legal name
Avisi Technologies, Inc.
Website
https://avisitech.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Avisi Technologies is a clinical-stage medical device company developing ultrathin nanotechnology-based glaucoma implants, including the VisiPlate aqueous shunt, targeting ophthalmologists and glaucoma specialists at hospitals and ambulatory surgery centers.
Ownership category
akta.pro rank

Avisi Technologies industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAI
Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Glaucoma treatment devices
  • Ophthalmic medical devices
  • Intraocular pressure management
  • Aqueous shunts
  • Nanotechnology ophthalmology

Where Avisi Technologies is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Avisi Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Sales (Pre-commercial): Avisi Technologies is currently a clinical-stage company with no commercial revenue. The company is conducting FDA clinical trials for VisiPlate. Once approved, the company expects to generate revenue through direct sales of its VisiPlate aqueous shunt devices to hospitals, ambulatory surgery centers, and ophthalmology practices treating glaucoma patients.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Avisi Technologies product offering

Product offering

Core offering

Avisi Technologies develops nanotechnology-enabled ophthalmic medical devices for the treatment of glaucoma and related eye conditions. Its core offering is VisiPlate, an investigational ultrathin (~5 micron) multichannel aqueous shunt made of patented alumina and Parylene-C metamaterial that controls intraocular pressure via redundant microchannels, with additional pipeline products including VisiPlate-S (suprachoroidal drainage device) and V-001 (sustained intraocular drug-delivery platform). The devices are manufactured using MEMS micro-fabrication techniques invented at the University of Pennsylvania.

Product overview

Avisi Technologies is a clinical-stage ophthalmic medical device company developing a portfolio of glaucoma treatment products leveraging proprietary nanotechnology and metamaterial technology. The core product is VisiPlate, an ultrathin multichannel aqueous shunt for moderate-severe glaucoma. This is complemented by VisiPlate-S, a suprachoroidal device designed for mild-moderate glaucoma during cataract surgery, and V-001, a sustained intraocular drug-delivery platform for dropless therapeutic delivery. The company uses MEMS (Micro-Electro-Mechanical Systems) manufacturing and advanced micro-fabrication techniques developed at the University of Pennsylvania.

Differentiator

Problem solved

Functional benefit

Products and services

  • VisiPlate VisiPlate is an investigational ultrathin multichannel aqueous shunt device designed to lower intraocular pressure in patients with open-angle glaucoma. The device is made of a patented metamaterial composition of alumina and Parylene-C, approximately 5 microns thick (several times thinner than a human hair), with multiple redundant microchannels that control aqueous drainage from the anterior chamber to the subconjunctival space. The non-fibrotic material design minimizes the scarring and blockage that causes failure of existing glaucoma surgical treatments.
  • VisiPlate-S VisiPlate-S is an investigational suprachoroidal drainage device designed for placement in the suprachoroidal space during cataract surgery to treat patients with mild-to-moderate primary open-angle glaucoma. The device is ultrathin, minimally invasive, soft and flexible, featuring a non-scarring design with a network of microchannels that create aqueous outflow through the suprachoroidal space via the uveoscleral pathway.
  • V-001 V-001 is a thin-film sustained intraocular drug-delivery platform designed to provide controlled, sustained release of therapeutics (including dexamethasone) in the anterior chamber. The platform aims to create a dropless patient experience by reducing the compliance burden associated with topical eye drops for glaucoma and other eye disease treatment.

Quantifiable outcome

  • 42.6% reduction in mean diurnal IOP at 12 months (from 24.1 to 13.1 mmHg)
  • +3 more outcomes

Companies that use Avisi Technologies

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Avisi Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Avisi Technologies partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • Johnson & Johnson JLABScoreStrategic or Co-development Partner · 1 January 2024Avisi is a member of JLABS, Johnson & Johnson's premier life science incubator. The company was part of the inaugural JPOD resident cohort receiving support from concept to commercialization.
  • UCSF Rosenman Innovator ProgramsupportingStrategic or Co-development Partner · 1 January 2020Selected for the Rosenman Innovators program supporting medtech startups with mentorship and resources for commercialization.
  • University of PennsylvaniacoreStrategic or Co-development Partner · 1 January 2017VisiPlate technology was invented at the University of Pennsylvania through the Singh Center for Nanotechnology. Avisi was founded through the Y-Prize program and received support from Penn Engineering labs. Scientific advisors hail from Penn's Scheie Eye Institute.
  • MedTech Innovator AcceleratorsupportingStrategic or Co-development Partner · 1 January 2017Alumni of the MedTech Innovator Accelerator program, which provides mentorship and support for medical technology companies.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Avisi Technologies competitors and assessment

Company assessment

Direct peers

  • Glaukos Corporation: Glaukos is the pioneer and market leader in MIGS devices (iStent family) for open-angle glaucoma. It is the most directly comparable peer to Avisi's VisiPlate, addressing the same patient population with similarly minimally invasive surgical implants targeting IOP reduction.
  • Sight Sciences: Sight Sciences markets the OMNI and Sustain systems, MIGS devices for glaucoma that combine trabecular and suprachoroidal outflow pathways. It directly competes with Avisi's VisiPlate and VisiPlate-S in the same ophthalmic surgical channels.
  • New World Medical: New World Medical manufactures traditional glaucoma drainage devices (Ahmed, Baerveldt implants) that compete with VisiPlate in moderate-to-severe open-angle glaucoma. It is a relevant peer for surgical shunts in the same procedural category.

Broad incumbents

  • Alcon: Alcon is a global ophthalmic medtech incumbent with a broad surgical and vision-care portfolio. It acquired Ivantis (Hydrus Microstent, a suprachoroidal MIGS device directly comparable to VisiPlate-S) and competes broadly across glaucoma surgical devices.
  • AbbVie (Allergan Aesthetics / Eye Care): AbbVie, through its Allergan acquisition, markets the Xen Gel Stent (subconjunctival drainage device) and a broad ophthalmic pharmaceutical portfolio. Xen is the closest large-pharma competitor to VisiPlate in mechanism and indication.
  • Johnson & Johnson Vision: Johnson & Johnson Vision is a leading ophthalmic medtech incumbent and the operator of JLABS, where Avisi is a resident company. J&J Vision sells cataract surgical products and has strategic interest in MIGS/glaucoma surgical adjacencies, making it both a competitor and potential acquirer.
  • Bausch + Lomb: Bausch + Lomb is a major ophthalmic medtech incumbent with surgical and pharmaceutical glaucoma offerings. Its broad portfolio and global distribution make it a strategic competitor and potential acquirer of emerging glaucoma device companies like Avisi.
  • Santen Pharmaceutical: Santen is a Japan-based global ophthalmology specialty pharmaceutical and device company with a substantial glaucoma franchise (including the InnFocus MicroShunt acquired from InnFocus). It is a strategic peer for both device and pharmaceutical glaucoma offerings overlapping Avisi's pipeline.

Emerging players

  • Iantrek: Iantrek is an early-to-growth-stage ophthalmic device company developing micro-invasive glaucoma surgical technologies, including canaloplasty and suprachoroidal approaches. It overlaps with Avisi in MIGS innovation targeting the same glaucoma surgeon customer base.
  • MicroOptx: MicroOptx is a clinical-stage ophthalmic medtech company developing a suprachoroidal glaucoma drainage implant. It is a direct emerging-stage peer to Avisi's VisiPlate-S in the same suprachoroidal mechanism of action.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Avisi Technologies social profiles

Digital presence

Avisi Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avisi Technologies leadership team

Management profile

Number of profiles

Profiles9 records

Avisi Technologies funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avisi Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avisi Technologies

What does Avisi Technologies do?

Avisi Technologies develops nanotechnology-enabled ophthalmic medical devices for the treatment of glaucoma and related eye conditions. Its core offering is VisiPlate, an investigational ultrathin (~5 micron) multichannel aqueous shunt made of patented alumina and Parylene-C metamaterial that controls intraocular pressure via redundant microchannels, with additional pipeline products including VisiPlate-S (suprachoroidal drainage device) and V-001 (sustained intraocular drug-delivery platform). The devices are manufactured using MEMS micro-fabrication techniques invented at the University of Pennsylvania.

Is Avisi Technologies a public or private company?

Avisi Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Avisi Technologies founded?

Avisi Technologies was founded in 2017. It employs 11 to 50 people.

Where is Avisi Technologies based?

Avisi Technologies is headquartered in Redwood City, United States, in the North America region.

How does Avisi Technologies make money?

One revenue line is on record: medical Device Sales (Pre-commercial).

Who are Avisi Technologies's main competitors?

Direct peers on record are Glaukos Corporation, Sight Sciences and New World Medical. Broad incumbents are Alcon, AbbVie (Allergan Aesthetics / Eye Care), Johnson & Johnson Vision, Bausch + Lomb and Santen Pharmaceutical. Emerging players are Iantrek and MicroOptx.

Does Avisi Technologies have an API?

No public API is recorded for Avisi Technologies.

What industry is Avisi Technologies in?

Avisi Technologies's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAI, Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty). Its NAICS code is 339115 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAvisi Technologies to Present VisiPlate® 2-year Data at American Academy of Ophthalmology Annual MeetingAvisi Technologies will present 2-year follow-up data from the VITA trial of its VisiPlate aqueous shunt at the 2026 American Academy of Ophthalmology meeting in New Orleans. Dr. Jonathan S. Myers will present the poster session on long-term efficacy and safety, with additional presentations on the device's design and surgical pearls.Ophthalmology TimesAvisi Technologies releases positive 12-month data from VITA TrialAvisi Technologies released positive 12-month clinical data from the VITA Trial for its VisiPlate Aqueous Shunt, showing a 42.6% reduction in mean diurnal intraocular pressure for open-angle glaucoma patients with no adverse events reported. The trial involved 15 patients in South Africa, and nearly half of participants were able to discontinue glaucoma medication after one year. Avisi is currently conducting the US-based SAPPHIRE Trial to further evaluate the device's safety and effectiveness.Ophthalmology TimesAvisi Technologies treats first patient in SAPPHIRE trial for glaucomaAvisi Technologies has treated the first patient in its international SAPPHIRE clinical trial for VisiPlate, a metamaterial-based shunt designed to treat open-angle glaucoma. The trial involves approximately 65 patients across 13 US locations and aims to evaluate the device's efficacy in reducing intraocular pressure over 12 months. This follows positive data from the earlier VITA trial in South Africa, which showed significant pressure reduction and no adverse events.Ophthalmology TimesAvisi Technologies releases 6-month interim results from VITA trialAvisi Technologies released positive 6-month interim results from the VITA trial for its investigational VisiPlate device, showing a 40.4% reduction in intraocular pressure in patients with open-angle glaucoma. The study of 15 patients demonstrated that 78.6% achieved significant pressure reduction while decreasing medication use, alongside a favorable safety profile with no loss of visual acuity. Surgeons reported the procedure was easier and faster than standard trabeculectomy, suggesting potential improvements in patient comfort and postoperative management.Eyes On EyecareAvisi raises $10.7M to advance study on VisiPlate glaucoma deviceAvisi Technologies has secured $10.7 million in Series A financing led by MedVenture Partners to fund the pivotal SAPPHIRE clinical trial evaluating its VisiPlate device for glaucoma treatment. The multicenter trial, initiated in November 2025 with an estimated completion in October 2027, is currently enrolling 165 patients across 16 clinic sites in eight U.S. states to assess the device's ability to reduce intraocular pressure. The financing will also support further development of the company's pipeline addressing the full spectrum of glaucomatous disease, building on prior positive 6-month pilot data showing a 40% reduction in mean IOP.Pulse 2.0Avisi Technologies: $10.7 Million Series A Raised To Advance Novel Glaucoma Device DevelopmentAvisi Technologies, a clinical-stage ophthalmic medical device company, closed a $10.7 million Series A financing round led by MedVenture Partners with participation from multiple new and existing healthcare investors to advance its VisiPlate glaucoma treatment device. The funding will primarily support the SAPPHIRE pivotal clinical trial, which received FDA Investigational Device Exemption approval in 2025 and is currently enrolling patients across the United States. VisiPlate features a patented metamaterial design engineered to sustainably reduce intraocular pressure by improving fluid outflow in the eye, addressing a condition affecting more than 133 million people worldwide.VC News DailyAvisi Technologies Announces $10.7M Series AAvisi Technologies, an ophthalmic medical device company based in Redwood City, California, has closed a $10.7 million Series A financing round. The round was led by MedVenture Partners with participation from new investors Sherpa Healthcare Partners, SNBL-Gemseki, SBI US Gateway Fund, Golden Seeds, and OneOneFive, as well as existing investors Good Growth Capital, Accanto Partners, Life Sciences Greenhouse Investment, and Quaker Capital Investments. The funding is intended to advance the company's novel, sight-saving ophthalmic technologies.PR NewswireAvisi Technologies Announces $10.7M Capital Raise to Advance Novel Glaucoma Device DevelopmentAvisi Technologies has closed a $10.7M Series A financing round led by MedVenture Partners, with participation from new investors Sherpa Healthcare Partners, SNBL-Gemseki, SBI US Gateway Fund, Golden Seeds, OneOneFive, and existing investors Good Growth Capital, Accanto Partners, Life Sciences Greenhouse Investment, and Quaker Capital Investments. The funding will support the SAPPHIRE pivotal trial evaluating the VisiPlate® glaucoma treatment device, which received FDA IDE approval in 2025, as well as further development of Avisi's pipeline of ophthalmic treatments. As part of the round, Justin Fukuyama of MedVenture Partners joins the company's Board of Directors.VentureRadarNew Funding Rounds in "Eye Care"Multiple companies in the eye care sector received venture funding for various innovative products and solutions, including ophthalmic devices, AI diagnostics, and vision screening tools. Notable funding rounds include a $10.7 million Series A for Avisi Technologies and a €3.5 million investment in Custom Surgical, among others.Venture Capital Access OnlineAvisi Technologies Announces $10.7M Capital Raise to Advance Novel Glaucoma Device DevelopmentAvisi Technologies announced the closing of a $10.7 million Series A financing round led by MedVenture Partners, with participation from multiple new and existing investors. The funding will support the SAPPHIRE pivotal clinical trial for VisiPlate, a novel glaucoma treatment device featuring a unique metamaterial design that is thinner than a human hair and received FDA IDE approval in 2025. The SAPPHIRE trial is currently enrolling across multiple sites in the US to evaluate the device's safety and efficacy in sustainably reducing intraocular pressure.